Crit Care:大剂量维生素C治疗对严重烧伤患者的影响

2019-12-14 xing.T MedSci原创

由此可见,如果在入院后前2天之内使用最低阈值10g,严重烧伤患者大剂量维生素C治疗可降低死亡率。尽管“大剂量”维生素C治疗尚无统一定义,但本研究表明,不同的“大剂量”治疗方案可能会改善患者预后。

维生素C是一种已被证实的抗氧化剂,大剂量可以减弱氧化应激和减少输液。然而,大剂量维生素C与降低死亡率之间的关系仍不明确。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,该研究旨在评估两种不同阈值下大剂量维生素C对重度烧伤患者的疗效。

研究人员招募了2010年至2016年在日本诊断程序联合国家住院患者数据库中注册的重度烧伤(烧伤指数≥15)的成年患者。在入院后1天内接受大剂量维生素C的患者(维生素C组)与未接受维生素C的患者(对照组)之间进行了倾向得分匹配。大剂量维生素C的定义是在入院后2天之内超过10g或24g的剂量。主要结局是院内死亡率。

符合条件的患者(n=2713)分为维生素C组(n=157)或对照组(n=2556)。在按1:4的倾向得分匹配后,研究人员比较了分别157名接受大剂量维生素C(>10 g阈值)和628名对照组的患者。在此特定阈值下,大剂量维生素C治疗可降低院内死亡率(风险比为0.79;95%置信区间为0.66-0.95;p=0.006)。相比之下,对照组和>24 g阈值的大剂量维生素C组受试者院内死亡率没有差异(风险比为0.83;95%置信区间为0.68-1.02;p=0.068)。

由此可见,如果在入院后前2天之内使用最低阈值10g,严重烧伤患者大剂量维生素C治疗可降低死亡率。尽管“大剂量”维生素C治疗尚无统一定义,但本研究表明,不同的“大剂量”治疗方案可能会改善患者预后。 

原始出处:

Mikio Nakajima.et al.Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study.Critical Care.2019.https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2693-1

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=953179, encodeId=78bc9531e99c, content=非常好的一篇文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Thu Apr 01 22:05:10 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674619, encodeId=84e916e46193d, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 24 01:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377043, encodeId=0af03e704361, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Dec 16 21:40:20 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578692, encodeId=145415e869252, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Mon Dec 16 00:03:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376940, encodeId=dada3e69404d, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Dec 14 10:33:51 CST 2019, time=2019-12-14, status=1, ipAttribution=)]
    2021-04-01 ms3000001627599051

    非常好的一篇文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=953179, encodeId=78bc9531e99c, content=非常好的一篇文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Thu Apr 01 22:05:10 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674619, encodeId=84e916e46193d, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 24 01:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377043, encodeId=0af03e704361, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Dec 16 21:40:20 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578692, encodeId=145415e869252, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Mon Dec 16 00:03:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376940, encodeId=dada3e69404d, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Dec 14 10:33:51 CST 2019, time=2019-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=953179, encodeId=78bc9531e99c, content=非常好的一篇文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Thu Apr 01 22:05:10 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674619, encodeId=84e916e46193d, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 24 01:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377043, encodeId=0af03e704361, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Dec 16 21:40:20 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578692, encodeId=145415e869252, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Mon Dec 16 00:03:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376940, encodeId=dada3e69404d, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Dec 14 10:33:51 CST 2019, time=2019-12-14, status=1, ipAttribution=)]
    2019-12-16 一个字-牛

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=953179, encodeId=78bc9531e99c, content=非常好的一篇文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Thu Apr 01 22:05:10 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674619, encodeId=84e916e46193d, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 24 01:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377043, encodeId=0af03e704361, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Dec 16 21:40:20 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578692, encodeId=145415e869252, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Mon Dec 16 00:03:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376940, encodeId=dada3e69404d, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Dec 14 10:33:51 CST 2019, time=2019-12-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=953179, encodeId=78bc9531e99c, content=非常好的一篇文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Thu Apr 01 22:05:10 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674619, encodeId=84e916e46193d, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 24 01:03:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377043, encodeId=0af03e704361, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Dec 16 21:40:20 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578692, encodeId=145415e869252, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Mon Dec 16 00:03:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376940, encodeId=dada3e69404d, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Dec 14 10:33:51 CST 2019, time=2019-12-14, status=1, ipAttribution=)]
    2019-12-14 184****9840

    学习了,谢谢分享。

    0

相关威廉亚洲官网

NEJM: 大剂量的维生素D才能降低骨折风险

《新英格兰医学杂志》7月4日在线发表的一项最新Meta分析显示,只有摄入大剂量的维生素D补充剂(≥800 IU/d)才能降低老年人的骨折风险。65岁以上老年人摄入大剂量补充剂可使髋关节骨折风险降低30%,非椎体骨折风险降低14%(N. Engl. J. Med. 2012 July 4 [doi: 10.1056/NEJMoa1109617])。    既往许多探讨维

大剂量使用β受体阻滞剂的有效性及安全性如何?

近期,一项多中心、随机、开放标签、平行组临床试验的结果发表在Int J Med Sci杂志上。本研究旨在探讨对使用小剂量β受体阻滞剂且心率控制不满意的中国稳定性心绞痛患者,琥珀酸美托洛尔95 mg和190 mg对心率控制的作用以及药物耐受性。基于此,williamhill asia 有幸采访了本项研究的主要研究者北京大学第一医院霍勇教授,就此研究中的相关问题与对临床实践的启示展开讨论。

Crit Care:早期大剂量糖皮质激素逐渐减量方案对急性呼吸窘迫综合征的负面效应!

由此可见,大剂量糖皮质激素治疗后逐渐减量的方案可能会增加呼吸机依赖性,并可能恶化根据柏林定义确诊的ARDS患者预后。

JAMA:大剂量多种维生素补充剂不能减少接受HAART患者死亡率

  据发表在10月17日发表在《美国医学会杂志》上的一项研究披露,在坦桑尼亚的感染了人类免疫缺陷性病毒(HIV)的病人中,与给予标准剂量的多种维生素补充剂相比,在开始具有高度活性的抗逆转录病毒疗法后给予高剂量的多种维生素补充剂不会减少HIV疾病进展的风险或死亡率,但却会导致某种肝脏酶水平增高的不良反应。   根据文章的背景资料:“在过去的15年间提供具有高度活性的抗逆转录病毒疗法(HAART)显

大剂量吗啡/舒芬太尼PCSA治疗难治性癌痛1例

2017年6月我科收治1例难治性癌性疼痛病人,男性,27岁,主因上颌骨骨肉瘤综合治疗后复发,颌面部疼痛入院。病人既往行上颌骨手术治疗2次,并行多周期放化疗治疗,此次以颌面部疼痛主诉入院,已属晚期,无放化疗指征。

Neurology:大剂量甲基强的松龙治疗急性创伤性脊髓损伤疗效

根据目前的证据,与对照组相比,高剂量MP治疗无助于更好的神经恢复,但可能增加ASCI患者不良事件的风险。因此,研究人员并不建议在ASCI后早期常规使用高剂量MP治疗。